Clinical relevance of MDM2 SNP 309 and TP53 Arg72Pro in follicular lymphoma

Haematologica

Volumn 94, Issue 1, 2009, Pages 148-150

  Wrench, David ^a   Waters, Rachel ^b   Carlotti, Emanuela ^a   Iqbal, Sameena ^a   Matthews, Janet ^c   Calaminici, Marie ^c   Gribben, John ^a   Lister, T Andrew ^a   Fitzgibbon, Jude ^c  

^a QUEEN MARY UNIVERSITY OF LONDON   (United Kingdom)

^b UNIVERSITY OF OXFORD   (United Kingdom)

^c BARTS HEALTH NHS TRUST   (United Kingdom)

Author keywords

Follicular; Lymphoma; MDM2; SNPs; TP53

Indexed keywords

ARGININE; MESSENGER RNA; PROLINE; PROTEIN MDM2;

APOPTOSIS; B CELL LYMPHOMA; CANCER RISK; CANCER SUSCEPTIBILITY; CELL CYCLE REGULATION; CELL TRANSFORMATION; CLINICAL ASSESSMENT; CLINICAL FEATURE; DISEASE COURSE; FOLLICULAR LYMPHOMA; GENE EXPRESSION; GENE FREQUENCY; GENE LOCUS; GENE MUTATION; GENOMICS; HISTOLOGY; HOMOZYGOSITY; LETTER; OVERALL SURVIVAL; PROGNOSIS; PROTEIN DEGRADATION; PROTEIN EXPRESSION; REAL TIME POLYMERASE CHAIN REACTION; SINGLE NUCLEOTIDE POLYMORPHISM; UPREGULATION;

ARGININE; DISEASE PROGRESSION; FEMALE; HUMANS; LYMPHOMA, FOLLICULAR; MALE; MUTATION; NEOPLASM STAGING; POLYMORPHISM, SINGLE NUCLEOTIDE; PROTO-ONCOGENE PROTEINS C-MDM2; SURVIVAL RATE; TUMOR SUPPRESSOR PROTEIN P53;

EID: 58149252351     PISSN: 03906078     EISSN: None     Source Type: Journal    
DOI: 10.3324/haematol.13533     Document Type: Letter

References (12)

1. Sander CA, Yano T, Clark HM, Harris C, Longo DL, Jaffe ES, et al. p53 mutation is associated with progression in follicular lymphomas. Blood 1993;82:1994-2004.
2. Lo Coco F, Gaidano G, Louie DC, Offit K, Chaganti RS, Dalla-Favera R. p53 mutations are associated with histologic transformation of follicular lymphoma. Blood 1993;82:2289-95.
3. Symmans WF, Katz RL, Ordonez NG, Dalton H, Romaguera JE, Cabanillas F. Transformation of follicular lymphoma. Expression of p53 and bcl-2 oncoprotein, apoptosis and cell proliferation. Acta Cytol 1995;39:673-82.
4. Davies AJ, Lee AM, Taylor C, Clear AJ, Goff LK, Iqbal S, et al. A limited role for TP53 mutation in the transformation of follicular lymphoma to diffuse large B-cell lymphoma. Leukemia 2005;19:1459-65.
5. Alt JR, Greiner TC, Cleveland JL, Eischen CM. Mdm2 haplo-insufficiency profoundly inhibits Myc-induced lymphomagenesis. Embo J 2003;22:1442-50.
6. Hong Y, Miao X, Zhang X, Ding F, Luo A, Guo Y, et al. The role of P53 and MDM2 polymorphisms in the risk of esophageal squamous cell carcinoma. Cancer Res 2005;65:9582-7.
7. Bond GL, Hirshfield KM, Kirchhoff T, Alexe G, Bond EE, Robins H, et al. MDM2 SNP309 accelerates tumor formation in a gender-specific and hormone-dependent manner. Cancer Res 2006;66:5104-10.
8. Gryshchenko I, Hofbauer S, Stoecher M, Daniel PT, Steurer M, Gaiger A, et al. MDM2 SNP309 is associated with poor outcome in B-cell chronic lymphocytic leukemia. J Clin Oncol 2008;26:2252-7.
9. Zenz T, Häbe S, Benner A, Kienle D, Döhner H, Stilgenbauer S. The MDM2 -309 T/G promoter single nucleotide polymorphism does not alter disease characteristics in chronic lymphocytic leukemia. Haematologica 2008;93:1111-3.
10. Thomas M, Kalita A, Labrecque S, Pim D, Banks L, Matlashewski G. Two polymorphic variants of wild-type p53 differ biochemically and biologically. Mol Cell Biol 1999;19:1092-100.
11. Ohmiya N, Taguchi A, Mabuchi N, Itoh A, Hirooka Y, Niwa Y, et al. MDM2 promoter polymorphism is associated with both an increased susceptibility to gastric carcinoma and poor prognosis. J Clin Oncol 2006;24:4434-40.
12. Zhang X, Miao X, Guo Y, Tan W, Zhou Y, Sun T, et al. Genetic polymorphisms in cell cycle regulatory genes MDM2 and TP53 are associated with susceptibility to lung cancer. Hum Mutat 2006;27:110-7.